Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for CNBX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
May 31, 2026 0.045M
February 28, 2026 0.035M
November 30, 2025 0.04M
August 31, 2025 0.03M
May 31, 2025 0.02M
February 28, 2025 0.08M
November 30, 2024 0.03M
August 31, 2024 0.0013M
May 31, 2024 0.0013M
February 29, 2024 0.00
November 30, 2023 0.025M
August 31, 2023 0.065M
May 31, 2023 0.015M
February 28, 2023 0.02M
November 30, 2022 0.00
August 31, 2022 0.1499M
May 31, 2022 0.24M
February 28, 2022 0.00
November 30, 2021 0.00
August 31, 2021 0.00
May 31, 2021 1.25M
February 28, 2021 1.207M
November 30, 2020 0.00
August 31, 2020 0.00
May 31, 2020 0.00
Date Value
February 29, 2020 0.00
November 30, 2019 0.00
August 31, 2019 0.00
May 31, 2019 0.00
February 28, 2019 0.0675M
November 30, 2018 7.150M
August 31, 2018 0.50M
May 31, 2018 -0.085M
February 28, 2018 1.05M
November 30, 2017 -0.022M
August 31, 2017 0.5556M
May 31, 2017 2.918M
February 28, 2017 0.4585M
November 30, 2016 0.406M
August 31, 2016 0.00
May 31, 2016 0.00
February 29, 2016 0.094M
November 30, 2015 0.02M
August 31, 2015 0.0302M
May 31, 2015 0.00
February 28, 2015 0.00
November 30, 2014 0.0783M
August 31, 2014
May 31, 2014 0.062M
February 28, 2014 0.0102M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 0.00
GB Sciences, Inc. --
Arvinas, Inc. 0.40M
Fulcrum Therapeutics, Inc. 0.356M
Definium Therapeutics, Inc. 758.70M

Cash from Financing (Quarterly) Related Metrics